![]() |
|
|
Vol. 303, Issue 3, 1265-1272, December 2002
Dipartimento di Biologia cellulare e dello Sviluppo, Università di Palermo, Palermo, Italy (F.M.); and Dipartimento Farmaco-Biologico, Università della Calabria, Arcavacata di Rende, Italy (M.C.B., M.F., M.C.C.)
| |
Abstract |
|---|
|
|
|---|
Recording simultaneously in vitro the changes of endoluminal
pressure (index of circular muscle activity) and isometric tension (index of longitudinal muscle activity), we examined the mechanisms responsible for the apamin-sensitive relaxant and contractile responses
induced by protease-activated receptor (PAR)-1 and PAR-2 activating
peptides, SFLLRN-NH2 and SLIGRL-NH2,
respectively, in rat colon. In the circular muscle, the inhibitory
effects of SFLLRN-NH2 and SLIGRL-NH2 were
significantly reduced by ryanodine, an inhibitor of Ca2+
release from the sarcoplasmic reticulum, but unaffected by
1-[6-[[17
-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122), a phospholipase C (PLC) inhibitor,
3-[1-[3-(dimethylaminopropyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione monohydrochloride (GF109203X), a protein kinase C (PKC)
inhibitor, or genistein, a tyrosine kinase inhibitor. In the
longitudinal muscle, the contractile responses to
SFLLRN-NH2 and SLIGRL-NH2 were significantly
reduced by nifedipine, an L-type calcium channel blocker, ryanodine,
GF109203X, genistein, and abolished by U73122. The effects of genistein
were additive with GF109203X but not with nifedipine. In the
longitudinal muscle, the relaxant responses to the highest
concentrations of SFLLRN-NH2 and SLIGRL-NH2
were abolished by nifedipine, reduced by genistein, and unaffected by
ryanodine or GF109203X. In conclusion, influx of extracellular Ca2+ through L-type voltage-dependent channels or release
of Ca2+ from intracellular stores are determining for the
opening of the apamin-sensitive K+ channels responsible for
longitudinal muscle relaxation or circular muscle inhibitory response,
respectively, in rat colon. The longitudinal muscle contraction is
mediated by activation of PLC; PKC and tyrosine kinase are involved in
the cascade process, playing a parallel role. Indeed, tyrosine kinase
and L-type Ca2+ channels would act sequentially. The influx
of Ca2+ in turn would cause release of Ca2+
from sarcoplasmic reticulum.
| |
Introduction |
|---|
|
|
|---|
Proteinase-activated
receptors (PARs) are a recently described novel family of
seven-transmembrane G-protein-coupled receptors, which are involved in
several pathophysiological processes, including inflammation (Dery et
al., 1998
; Schmidlin and Bunnett, 2001
; Vergnolle et al., 2001
). Rather
than being stimulated through ligand receptor occupancy, activation is
initiated by cleavage of their extracellular N-terminal domain by a
serine protease resulting in the generation of a new "tethered
ligand" binding and activating the receptor itself (Dery et al.,
1998
; Macfarlane et al., 2001
). To date, four PARs have been
identified: PAR-1 and PAR-3 both preferentially activated by thrombin
(Vu et al., 1991
; Ishihara et al., 1997
), PAR-2, which selectively
activated by trypsin or mast-cell tryptase (Nystedt et al., 1994
;
Molino et al., 1997
), and PAR-4, activated by thrombin or trypsin (Xu et al., 1998
). Short synthetic peptides based on the proteolytically revealed receptor sequences (PAR-activating peptides) can selectively activate PAR-1, PAR-2, or PAR-4, but thus far, activating peptides for
PAR-3 have not been identified.
Numerous studies have been performed to clarify the role of PARs in the
physiology and pathophysiology of the gastrointestinal tract because
these tissues, more than others, are exposed to proteinases and PARs
are highly expressed throughout the gastrointestinal tract (Vergnolle,
2000
). PAR-2 appears to be involved in exocrine secretion (Nguyen et
al., 1999
; Kawabata et al., 2000c
) and intestinal ion transport
(Vergnolle et al., 1998
). PAR-1 and PAR-2 modulate smooth muscle
motility (Kawabata et al., 2001
), and their activation can induce
relaxant, contractile, or biphasic responses (Al-Ani et al., 1995
;
Saifeddine et al., 1996
; Corvera et al., 1997
; Hollenberg et al., 1997
,
1999
; Zheng et al., 1998
; Cocks et al., 1999
; Kawabata et al., 1999
,
2000a
; Tognetto et al., 2000
; Mulè et al., 2002
).
The signal transduction mechanisms coupled with PAR activation do not
necessarily appear to be the same in distinct tissues. Extracellular
Ca2+ influx, activation of tyrosine kinase,
activation of phospholipase C (PLC) with consequent increase of
inositol 1,4,5-trisphosphate and diacylglycerol, formation of
metabolites of arachidonic acid, and activation of apamin-sensitive
K+ channels are the main mechanisms reported to
be involved in the biochemical transduction (Hollenberg et al., 1993
,
1997
, 1999
; Zheng et al., 1998
; Cocks et al., 1999
; Kawabata et al.,
1999
, 2000a
,b
; Mulè et al., 2002
). To date, however, it is
unclear if these mechanisms represent different steps of a single
cascade or are parallel signal transduction pathways.
In our previous study, a role of PAR-1 and PAR-2 receptors in the
stimulation of the intestinal transit was hypothesized in rat colon
because PAR activation induced different mechanical responses on the
two muscular layers: an inhibitory effect on the circular muscle and a
contractile effect, which became biphasic at the highest concentration
used, in the longitudinal muscle (Mulè et al., 2002
). In rat
colon, an involvement of products of cyclooxygenase in the action of
PAR-1 and PAR-2 activating peptides was ruled out. The inhibitory
responses to PAR-1 and PAR-2 agonists mainly occurred via activation of
apamin-sensitive K+ channels, but the source of
Ca2+ necessary to activate the
K+ channels was not investigated.
The present study was undertaken in the attempt to characterize the signal transduction mechanisms for the rat colonic relaxant and/or contractile responses due to PAR-1 and PAR-2 activation. Specifically, we examined 1) the relative contribution of intracellular and extracellular Ca2+, 2) the possible involvement of PLC, protein kinase C (PKC), and tyrosine kinase in the inhibitory and contractile responses to PAR-1 and PAR-2 activation, and 3) the sequence of events leading to the contraction.
| |
Materials and Methods |
|---|
|
|
|---|
Tissue Preparation and Mechanical Recording.
Colonic
segments were obtained from male Wistar rats weighing 250 to 400 g. Animals were cared for in accordance with the Declaration of
Helsinki and were killed by rapid cervical dislocation. The abdomen was
immediately open, and the colon was removed. The colonic lumen was
cleaned with Krebs' solution, and three segments of about 2 cm in
length were cut proximally to caecum. The preparation was then placed
in a continuously perfused horizontal organ bath containing 5 ml of
gassed (95% O2 and 5%
CO2) Krebs' solution with the following
composition: 119 mM NaCl, 4.5 mM KCl, 2.5 mM MgSO4, 25 mM NaHCO3, 1.2 mM
KH2PO4, 2.5 mM
CaCl2, and 11.1 mM glucose. The solution was
maintained at 37°C. As previously described (Mulè et al.,
2002
), the distal end of the intestinal segment was tied around the
mouth of a J-tube, which was connected via a T catheter to a standard
pressure transducer (Ugo Basile, Biological Research Apparatus, Varese,
Italy) and to a syringe for filling the preparation with Krebs'
solution. The ligated proximal end was secured with a silk thread to an
isometric force transducer (DY2; Ugo Basile). Preparations, filled with
0.1 ml of Krebs' solution, were subjected to an initial tension of
1 g and were allowed to equilibrate for at least 30 min before
starting the experiment. Colonic contractions were monitored as changes
in intraluminal pressure and isometric tension, which are mainly generated by circular and longitudinal muscle activity, respectively. Mechanical activities were recorded on an ink writer recorder (Gemini,
Ugo Basile). The correspondence of the intraluminal pressure and
tension recordings to the mechanical activity of circular and
longitudinal muscle, respectively, has been already demonstrated in our
previous studies (Mulè et al., 1992
; 1999
).
Experimental Protocol.
After the equilibration period, the
preparation was challenged with carbachol at 10 µM, which in
preliminary experiments was demonstrated to induce maximal effect.
Then, the responses of the preparations to cumulative concentrations of
PAR-activating peptides were examined in the absence and presence of
different inhibitors/antagonists. In some experiments, we confirmed
that the noncumulative addition of the peptides caused reproducible concentration-response curves. The peptides tested were
SFLLRN-NH2 (0.01-10 µM), a PAR-1 agonist that
is reported to have weak agonistic activity toward PAR-2 (Hollenberg et
al., 1997
), and SLIGRL-NH2 (0.01-10 µM), a
murine PAR-2-specific agonist (Nystedt et al., 1994
). We previously
demonstrated that in our preparation, SFLLRN-NH2 mimicked the effects of TFLLR-NH2, a highly
specific PAR-1 analog (Hollenberg et al., 1997
), and that the response
to SFLLRN-NH2 was not affected by prior
desensitization to SLIGRL-NH2 (Mulè et al.,
2002
). Therefore, the responses to SFLLRN-NH2 in
the present study have to be considered to result from activation of
PAR-1. The peptides were added into the bath in volumes of 50 µl
after switching off the perfusion. Each concentration was left in
contact with the tissue for 2 min. The inhibitors/antagonists were the following: nifedipine, an L-type Ca2+ channel
inhibitor (1 µM), ryanodine, an inhibitor of
Ca2+-induced Ca2+ release
from the sarcoplasmic reticulum (10 µM), U73122, a PLC inhibitor
(0.5-5 µM), GF109203X, a protein kinase C inhibitor (1 µM), and
genistein, a tyrosine kinase inhibitor (1-10 µM). For the most of
the drugs, the concentration used was known to be effective in our and
other systems (Mulè and Serio, 1997
; Cocks et al., 1999
; Kawabata
et al., 2000b
). Some antagonists were coadministered to clarify if the
effectors represent different steps of the same pathway. These agents
were added to the perfusing solution at least 30 min before testing the
PAR-activating peptides. Sometimes to verify the specificity of the
effect observed, the responses to carbachol (1 µM) or isoproterenol
(1 µM) at concentrations shown to be submaximal were evaluated in the
absence and in the presence of the inhibitors.
Data Analysis and Statistics.
The inhibitory response of the
circular muscle to PAR-1 and PAR-2 activation was taken as the percent
change from the resting spontaneous activity (e.g.,
100% corresponds
to the abolition of spontaneous activity). In this view, the mean
amplitude of the pressure waves was determined for 10 min before and
after administration of agonists. The contractile response of the
longitudinal muscle was defined as a change in the resting tone (the
bottom level of the tension oscillations) and was expressed as a
percentage of the contraction caused by 10 µM carbachol. All data
obtained are expressed as mean ± S.E. n indicates the
number of animals from which an intestinal segment was taken.
Statistical analyses were performed by a Student's paired t
test for comparison between two-group data (responses in the absence
and in the presence of inhibitors) or by analysis of variance, followed
by a Bonferroni test for multiple treatment comparison.
P < 0.05 was regarded as significant.
Drugs. The following drugs were used: carbamylcholine chloride (carbachol), isoprenaline hydrochloride, ryanodine (Sigma-Aldrich, St. Louis, MO), nifedipine, bisindolylmaleimide I (GF109203X), genistein, U73122, and phorbol-12,13-dibutyrate (Calbiochem, Darmstadt, Germany). SFLLRN-NH2 was obtained from Bachem (Bubendorf, Switzerland), and SLIGRL-NH2 was supplied by Dr. D. McMaster of the Peptide Synthesis Core Facility at the University of Calgary (Calgary, AB, Canada). PAR-related peptides were prepared by standard solid-phase synthesis procedures. The concentration, purity, and composition of the peptides were determined by high-performance liquid chromatography, mass spectrometry, and quantitative amino acid analysis. Ryanodine was dissolved in ethanol. Nifedipine, U73122, GF109203X, and genistein were dissolved in dimethyl sulfoxide. All other chemicals were dissolved in distilled water. Control tests showed that the solvents alone had no effect on the preparation. To avoid photodecomposition, experiments with nifedipine and genistein were performed with no external lighting.
| |
Results |
|---|
|
|
|---|
As previously described (Mulè et al., 2002
), the PAR-1 and
PAR-2 peptide activators SFLLRN-NH2 (10 nM-10
µM) and SLIGRL-NH2 (10 nM-10 µM),
respectively, which are mimetic of each tethered ligand sequence,
caused different effects on the two muscular layers. They produced an
inhibitory response consisting in a concentration-dependent reduction
in the amplitude of the spontaneous rhythmic contractions of the
circular muscle and a contractile response in the longitudinal muscle,
at least at the lowest concentrations tested. In fact, in the
longitudinal muscle, a biphasic effect, relaxation followed by
contraction, in response to the PAR-1 and PAR-2 activating peptides was
observed (Fig. 1) at concentrations over
1 µM.
|
Role of Extracellular and Intracellular Calcium.
To
investigate the involvement of Ca2+ in the
responses due to PAR-1 and PAR-2 activation and the relative
contribution of the extracellular and intracellular source, we used
nifedipine, an L-type voltage-dependent calcium channel blocker, and
ryanodine, an inhibitor of Ca2+-induced
Ca2+ release from the sarcoplasmic reticulum.
Nifedipine at 1 µM greatly reduced the spontaneous phasic
contractions of the colonic segments; therefore, its effects on the
inhibitory response in the circular muscle could not to be evaluated.
In the longitudinal muscle, nifedipine significantly reduced the
contractile effects induced by the activation of PAR-1 and PAR-2, and
it abolished the relaxation in response to the highest
concentrations of the PAR-1 and PAR-2 activating peptides without
affecting the relaxation to isoproterenol (1 µM) (Fig.
2; Table
1). Moreover, the contraction to
carbachol (1 µM) was not significantly modified in the presence of
nifedipine (2.5 ± 0.2 g before and 2.3 ± 0.3 g
after nifedipine, n = 5, P > 0.05).
Ryanodine (10 µM) by itself did not modify the mechanical spontaneous
activity or the contraction to carbachol (1 µM) (2.8 ± 0.4 g before and 2.6 ± 0.5 g after ryanodine, n = 7, P > 0.05). It significantly reduced both the
inhibitory effects on the circular muscle and the contractile effects
on the longitudinal muscle induced by activation of PAR-1 and PAR-2
(Fig. 3). It failed to affect the
longitudinal muscle relaxation in response to
SFLLRN-NH2 (1-10 µM) or
SLIGRL-NH2 (10 µM) (Table 1).
|
|
|
Effects of Inhibitors of PLC, PKC, and Tyrosine Kinase.
In the
rat duodenal smooth muscle, the PAR-1-induced effect depends on the
activation of PLC and PKC (Kawabata et al., 1999
; 2000b
); therefore, we
verified the involvement of these enzymes in the signal transduction
responsible for the PAR-1- and PAR-2-induced effects in rat colon.
U73122 (0.5-1 µM), a PLC inhibitor, significantly reduced the PAR-1-
and PAR-2-induced contraction in a concentration-dependent manner (Fig.
4). U73122 at a concentration of 5 µM,
which slightly reduced the spontaneous contractions, abolished the
contractile response of the longitudinal muscle to
SFLLRN-NH2 and SLIGRL-NH2 but did not modify the inhibitory response on the circular muscle (Fig.
4). In the presence of U73122, the longitudinal muscle relaxation in
response to high concentrations of the PAR-1 and PAR-2 peptides could
not be observed, probably due to lacking of mechanical tone. GF109203X
(1 µM), a PKC inhibitor, which per se failed to affect the
spontaneous activity, significantly reduced the PAR-1- and
PAR-2-induced longitudinal muscle contractile effect without affecting
the relaxation (Fig. 5 and Table 1). In
the presence of GF109203X, the inhibitory response to peptides of the
circular muscle persisted unaltered (Fig. 5). Moreover, GF109203X at 1 µM was found to completely block contractions elicited in the
preparation by the PKC activator phorbol dibutyrate.
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
The present results suggest that the signal pathways activated by PAR-1 and PAR-2 receptors to cause contractile or inhibitory responses are the same in rat colon. Activation of PLC, PKC, tyrosine kinase, and intracellular and extracellular calcium are involved in the contractile effects of the longitudinal muscle. Influx of extracellular Ca2+ through L-type voltage-dependent channels or release of Ca2+ from intracellular stores are determining for the opening of the apamin-sensitive K+ channels responsible for longitudinal muscle relaxation or circular muscle inhibitory response, respectively.
Based on our own recent data (Mulè et al., 2002
) and on work of
others (Hamilton and Cocks, 2000
), we are confident that our results,
using the receptor-activating peptide SFLLRN-NH2, reflect the selective activation of PAR-1 and not of PAR-2 because SFLLRN-NH2 mimicked the effects of
TFLLR-NH2, a highly specific PAR-1 analog
(Hollenberg et al., 1997
), and the response to
SFLLRN-NH2 was not affected by prior
desensitization to SLIGRL-NH2.
The intestinal smooth muscle responses and the signal transduction
mechanisms coupled with PAR activation do not appear to be the same in
the intestinal smooth muscle and depend on the tissues and the animal
species. Moreover, the signal transduction pathways triggered by PAR-1
and PAR-2 are complex and the "cascade" processes are not
completely understood. In fact, although activation of L-type calcium
channels, cyclooxygenase, protein kinase C, and tyrosine kinase for
contractile effects (Hollenberg et al., 1992
; Zheng et al., 1998
;
Kawabata et al., 1999
; Kawabata et al., 2000b
) and activation of
apamin-sensitive K+ channels for relaxant effects
(Cocks et al., 1999
; Kawabata et al., 1999
, 200b; Mulè et al.,
2002
) appear to be involved, the sequence of events leading to
intestinal smooth muscle contraction or relaxation has not been yet
clarified. Moreover, indomethacin-sensitive cyclooxygenase products
might act in parallel to drive the effects. In our preparation,
however, no role for cyclooxygenase products in PAR-mediated responses
was previously pointed out (Mulè et al., 2002
).
In our preparation, the contractile responses to PAR-1 and PAR-2
activating peptides were greatly reduced by nifedipine suggesting that
contractile effects to PAR-1 and PAR-2 are mediated through the
activation of L-type Ca2+ channels. Moreover,
nifedipine also abolished the relaxation of the longitudinal muscle
evoked by PAR-1 and PAR-2 peptide agonists, which we previously
demonstrated to be apamin-sensitive. This finding suggests that the
activation of the apamin-sensitive, Ca2+-activated, small conductance
K+ channels is also mediated by calcium influx
through L-type channels. A similar result was reported in mouse gastric
fundus (Cocks et al., 1999
). It is likely that the calcium
concentration enhances in close proximity to the sarcolemma, evoking
outward hyperpolarizing currents due to opening of apamin-sensitive
K+ channels and subsequent closure of the
voltage-dependent Ca2+ channels responsible for
the relaxation in response to the high concentrations of
SFLLRN-NH2 and SLIGRL-NH2.
The specificity of the effect of nifedipine was confirmed by the
findings that the inhibitor of the Ca2+ channels
did not alter the contraction to carbachol or the relaxation induced by
isoproterenol. The finding that both the longitudinal muscle
contraction and the circular muscle inhibitory effects induced by PAR-1
and PAR-2 activating peptides were also inhibited by ryanodine, an
inhibitor of Ca2+-induced
Ca2+ release from the sarcoplasmic reticulum,
suggests that Ca2+ release from the sarcoplasmic
reticulum triggered by PAR activation contributes to the contraction
and it is somehow linked to the circular muscle inhibitory effect in
this tissue. Therefore, in the circular muscle,
Ca2+ derived from sarcoplasmic reticulum is
involved in the activation of the apamin-sensitive
K+ channels, which are responsible for the
inhibitory effects. PAR-1- and PAR-2-mediated relaxation via
ryanodine-sensitive and -insensitive activation of small-conductance,
Ca2+-activated K+ channels
has been previously reported in mouse gastric fundus (Cocks et al.,
1999
).
Moreover, our data imply that the contraction of the rat colonic
longitudinal muscle evoked by the activation of PAR-1 and PAR-2 is
mediated by PLC and, in addition, the activation of PKC and tyrosine
kinase participate in the signaling transduction. In fact, the
inhibitor of PLC, U73122, antagonized the contractile responses in a
concentration-dependent manner to PAR-1 and PAR-2 agonists in the
longitudinal muscle, up to blocking it, without affecting the
inhibitory response in the circular muscle, indicating that the
contraction is entirely dependent by activation of PLC. Partial
involvement of PLC in the PAR-1-mediated rat duodenal muscle has been
already reported (Kawabata et al., 2000b
). Moreover, we tested the
possible involvement of PKC and tyrosine kinase because it is well
known that PLC produces diacylglycerol that in turn activates PKC and
recent data indicate that tyrosine kinase is also involved in the
signal transduction associated with rat intestinal contractions (Ohta
et al., 2000
) or relaxation (Takeuchi et al., 1999
) through the
modulation of L-type calcium channels or apamin-sensitive
K+ channels, respectively. In our preparation,
the protein kinase C inhibitor GF109203X at a concentration sufficient
to block contraction induced by a PKC activator, phorbol dibutyrate,
and the tyrosine kinase inhibitor genistein concentration dependently
significantly reduced, but not abolished, the contractile effects,
indicating an involvement of both enzymes in the mechanism triggered by
PAR-1 or PAR-2 activation. The observation that the combined inhibitory effect of the two-protein kinase inhibitors was greater than that of
each one suggests that the activation of PKC and tyrosine kinase are
two distinct steps of different pathways acting in parallel. On the
contrary, the suppressive effects induced by genistein were not
additive with those induced by nifedipine suggesting that tyrosine
kinase and Ca2+ channels probably represent two
steps of the same sequential pathway leading to contraction. One
suggested hypothesis is that genistein inhibits the activation of the
Ca2+ channels. In fact, tyrosine phosphorylation
has been reported to modulate the L-type calcium channels (Liu
and Sperelakis, 1997
; Evans and Pocock, 1999
). Our pharmacological
data, however, do not allow us to establish whether phosphorylation of
the Ca2+ channels occurs in rat colon or to
clarify which type of tyrosine kinase is involved. In fact, genistein
is reported to be a tyrosine kinase broadly specific inhibitor at the
ATP-binding site (Akiyama et al., 1987
). Further experiments using
biomolecular techniques will need to clarify this point.
It is interesting to note that the PAR-induced relaxation of the longitudinal muscle was significantly also reduced by genistein, indicating that tyrosine kinase is involved in the regulation of the apamin-sensitive K+ channels in this tissue, although it was not possible establish whether the action of phosphorylation is direct or via other kinases. Tyrosine kinase and PKC, however, do not participate in the mechanism responsible for the inhibitory effects observed in circular muscle in response to PAR-1 and PAR-2 activating peptides.
In conclusion, PAR-1 and PAR-2 mediate inhibitory effects in the circular muscle via apamin-sensitive K+ channels in which activation depends on Ca2+ released from intracellular store. The contraction of the longitudinal muscle in response to PAR-1 and PAR-2 activating peptides is mediated by activation of PLC. In the cascade process, tyrosine kinase and PKC play a parallel role, whereas tyrosine kinase and L-type Ca2+ channels would act sequentially. The influx of Ca2+ in turn would cause release of Ca2+ from sarcoplasmic reticulum. The longitudinal muscle relaxation in response to high concentrations of PARs depends on apamin-sensitive K+ channels, opened by influx of Ca2+ through L-type channels, and modulated by tyrosine kinase.
| |
Footnotes |
|---|
Accepted for publication August 29, 2002.
Received for publication July 9, 2002.
This work was supported by a grant from Ministero dell'Università e della Ricerca scientifica, Italy.
DOI: 10.1124/jpet.102.041301
Address correspondence to: Flavia Mulè, Dipartimento di Biologia cellulare e dello Sviluppo Laboratorio di Fisiologia generale Università di Palermo Viale delle Scienze 90128 Palermo, Italia. E-mail: fmule{at}unipa.it
| |
Abbreviations |
|---|
PAR, protease-activated receptor;
PLC, phospholipase C;
PKC, protein kinase C;
U73122, 1-[6-[[17
-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione;
GF109203X, bisindolylmaleimide I,
3-[1-[3-(dimethylaminopropyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione
monohydrochloride.
| |
References |
|---|
|
|
|---|
novel signals for gastrointestinal pathophysiology.
Aliment Pharmacol Ther
14:
257-266[CrossRef][Medline].This article has been cited by other articles:
![]() |
T. Nishiyama, T. Nakamura, K. Obara, H. Inoue, K. Mishima, N. Matsumoto, M. Matsui, T. Manabe, K. Mikoshiba, and I. Saito Up-Regulated PAR-2-Mediated Salivary Secretion in Mice Deficient in Muscarinic Acetylcholine Receptor Subtypes J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 516 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Vergnolle CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT Gut, June 1, 2005; 54(6): 867 - 874. [Full Text] [PDF] |
||||
![]() |
M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Oshiro, H. Otani, Y. Yagi, S. Fukuhara, and C. Inagaki Protease-Activated Receptor-2-Mediated Inhibition for Ca2+ Response to Lipopolysaccharide in Guinea Pig Tracheal Epithelial Cells Am. J. Respir. Cell Mol. Biol., June 1, 2004; 30(6): 886 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zhao and T. Shea-Donohue PAR-2 agonists induce contraction of murine small intestine through neurokinin receptors Am J Physiol Gastrointest Liver Physiol, October 1, 2003; 285(4): G696 - G703. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||